Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz JE, Ahlers J, Richman DD, Sekaly RP.

Lancet. 2013 Jun 15;381(9883):2109-17. doi: 10.1016/S0140-6736(13)60104-X. Epub 2013 Mar 29. Review.

PMID:
23541541
2.

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.

Pierson T, McArthur J, Siliciano RF.

Annu Rev Immunol. 2000;18:665-708. Review.

PMID:
10837072
3.

Finding a cure for HIV: will it ever be achievable?

Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N.

J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4.

PMID:
21255462
4.

From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Shan L, Siliciano RF.

Bioessays. 2013 Jun;35(6):544-52. doi: 10.1002/bies.201200170. Epub 2013 Apr 24. Review.

PMID:
23613347
5.

Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.

Sluis-Cremer N.

Curr Top Med Chem. 2016;16(10):1191-7. Review.

PMID:
26324046
6.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.

Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, Barrett S, Howell B, Margolis D, Hazuda DJ, Archin NM, Garcia JV.

Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.

PMID:
27206407
7.

The challenge of finding a cure for HIV infection.

Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ.

Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706. Review.

PMID:
19265012
8.

The challenge of viral reservoirs in HIV-1 infection.

Blankson JN, Persaud D, Siliciano RF.

Annu Rev Med. 2002;53:557-93. Review.

PMID:
11818490
9.

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

Olesen R, Vigano S, Rasmussen TA, Søgaard OS, Ouyang Z, Buzon M, Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Østergaard L, Tolstrup M, Lichterfeld M.

J Virol. 2015 Oct;89(20):10176-89. doi: 10.1128/JVI.01484-15. Epub 2015 Jul 29.

PMID:
26223643
10.

Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, Lecuroux C, Rouzioux C, Boufassa F, Pancino G, Venet A, Van Lint C, Martinez-Picado J, Lambotte O, Sáez-Cirión A, Prado JG.

J Virol. 2016 Jun 10;90(13):6148-58. doi: 10.1128/JVI.00419-16. Print 2016 Jul 1.

PMID:
27122576
11.

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.

Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, Ashworth R, Gange S, Quinn TC, Siliciano RF, Persaud D.

J Virol. 2002 Sep;76(18):9481-92.

PMID:
12186930
13.

HIV infection: what should be considered in approaches for a cure?

Levy JA, Levy Y.

AIDS. 2012 Nov 13;26(17):2253-5. doi: 10.1097/QAD.0b013e32835ac83a. No abstract available.

PMID:
23060292
14.

Latently infected cell activation: a way to reduce the size of the HIV reservoir?

Forde J, Volpe JM, Ciupe SM.

Bull Math Biol. 2012 Jul;74(7):1651-72. doi: 10.1007/s11538-012-9729-x. Epub 2012 May 5.

PMID:
22562387
15.

Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.

Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, Nelson A, Hallahan CW, Moir S, Wender PA, Fauci AS.

J Infect Dis. 2012 Sep 1;206(5):765-9. doi: 10.1093/infdis/jis412. Epub 2012 Jun 25.

PMID:
22732922
16.

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.

Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST.

MBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.

PMID:
26152583
17.

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD.

N Engl J Med. 1999 May 27;340(21):1605-13.

PMID:
10341272
18.

HIV/AIDS eradication.

Marsden MD, Zack JA.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4003-10. doi: 10.1016/j.bmcl.2013.05.032. Epub 2013 May 18. Review.

PMID:
23735743
19.

The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients.

Pogliaghi M, Papagno L, Lambert S, Calin R, Calvez V, Katlama C, Autran B.

AIDS. 2014 Jan 14;28(2):278-81. doi: 10.1097/QAD.0000000000000073.

PMID:
24361684
20.

Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.

North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA.

J Virol. 2010 Mar;84(6):2913-22. doi: 10.1128/JVI.02356-09. Epub 2009 Dec 23.

PMID:
20032180

Supplemental Content

Support Center